HalesCM, CarrollMD, FryarCD, OgdenCL: Prevalence of obesity among adults and youth: United States, 2015–2016. NCHS Data Brief, 2017; 1–8.
2.
SiddiqueSS, FeurersteinJD: Gastrointestinal complications of Roux-en-Y gastric bypass surgery. OA Minim Invasive Surg, 2104; 2:1.
3.
CoblijnUK, GouchamAB, LagardeSM, et al.: Development of ulcer disease after Roux-en-Y gastric bypass, incidence, risk factors, and patient presentation: A systematic review. Obes Surg, 2014; 24:299.
4.
SchulmanAR, ThompsonCC: Abdominal pain in the Roux-en-Y gastric bypass patient. Am J Gastroenterol, 2018; 113:161–166.
5.
QuidleyAM, BlandCM, BookstaverPB, KuperK: Perioperative management of bariatric surgery patients. Am J Health Syst Pharm, 2014; 71:1253–1264.
6.
PadwalR, BrocksD, SharmaA: A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev, 2010; 11:41–50.
7.
MillerAD, SmithKM: Medication and nutrient administration considerations after bariatric surgery. Am J Health Syst Pharm, 2006; 63:1852–1857.
8.
HachonL, ReisR, LabatL, et al.: Morphine and metabolites plasma levels after administration of sustained release morphine in Roux-en-Y gastric bypass subjects versus matched control subjects. Surg Obes Relat Dis, 2017; 13:1869–1874.
9.
KriegerCA, CunninghamJL, ReidJM, et al.: Comparison of bioavailability of single-dose extended-release venlafaxine capsules in obese patients before and after gastric bypass surgery. Pharmacotherapy, 2017; 37:1374–1382.
10.
MechanickJ, YoudimA, JonesD, et al.: Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: Cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity, 2013; 21:S1–S27.
11.
HamadGG, HelselJC, PerelJM, et al.: The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry, 2012; 169:256–263.
12.
RoerigJL, SteffenKJ, ZimmermanC, et al.: A comparison of duloxetine plasma levels in postbariatric surgery patients versus matched nonsurgical control subjects. J Clin Psychopharmacol, 2013; 33:479–484.
13.
AdamsTD, GressRE, SmithSC, et al.: Long-term mortality after gastric bypass surgery. N Engl J Med, 2007; 357:753–761.
14.
CarpenterM, PisanoM, BlandC: Implications of bariatric surgery on absorption of nutrients and medications. US Pharm, 2016; 41:HS2–HS8.
15.
SteinJ, StierC, RaabH, WeinerR: Review article: The nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther, 2014; 40:582–609.
16.
AxelssonKF, WerlingM, EliassonB, et al.: Fracture risk after gastric bypass surgery: A retrospective cohort study. J Bone Miner Res, 2018; 33:2122–2131.
17.
ShanbhogueVV, StøvingRK, FrederiksenKH, et al.: Bone structural changes after gastric bypass surgery evaluated by HR-pQCT: a two-year longitudinal study. Eur J Endocrinol, 2017; 176:685–693.
18.
CorbeelsK, VerlindenL, LannooM, et al.: Thin bones: Vitamin D and calcium handling after bariatric surgery. Bone Rep, 2018; 8:57–63.
19.
VeeversAE, OxberrySG: Ranitidine: forgotten drug of delayed gastric emptying. BMJ Support Palliat Care, 2017; 7:255–257.
